Key features and details | |
Cat. No. | MABL-249 |
Name | Anti-Nicotine mAbs |
Clone No. | AFD-NIC9D9 |
From | Recombinant Antibody |
Isotype | Engineer antibody |
Application | immunotherapy, ELISA |
Species Reactivity | Species independent |
Basic Information | |
Specificity | This antibody is highly specific for S-(–)-nicotine. Nicotine is a plant alkaloid, found in the tobacco plant and other plants of the nightshade family. It is an addictive central nervous system (CNS) stimulant that causes either ganglionic stimulation in low doses or ganglionic blockage in high doses. It is the main psychoactive ingredient in tobacco products and a major component of cigarettes, which is also is used therapeutically to help with smoking cessation and reduce withdrawal symptoms. |
Alternative Name | Nicotin; rac-3-(1-methylpyrrolidin-2-yl)pyridine; CAS: 54-11-5; CHEBI:18723; Nic12; 9D9 |
UniProt | |
Immunogen | The original antibody was generated by immunizing mice with keyhole limpet hemocyanin (KLH) conjugated nicotine hapten. |
Application Notes | The binding characterization of this antibody to nicotine-BSA hapten was done using ELISA (PMID: 11397142). A study to determine the effect of vaccination with this antibody towards a series of nicotine challenges and testing sessions was conducted. Passive immunization with NIC9D9 resulted in a 66.9% decrease in locomotor activity versus a 3.4% decrease in controls (PMID: 14738965). This antibody was also used in the generation of an adeno-associated virus (AAV) gene transfer vector which persistently expresses this antibody in vivo and prevents nicotine from reaching its receptors in the brain. This vector is called AAVantiNic and it generates an antibody similar to Nic9D9 that binds nicotine with an affinity of Kd= 43 nM. The mice treated with this vector showed 7 times greater amounts of nicotine in the serum of which 83% was bound to IgG. The vector blocked nicotine-mediated alterations in arterial blood pressure, heart rate and locomotor activity (PMID: 22745437). |
Antibody First Published | Carrera et al. Investigations using immunization to attenuate the psychoactive effects of nicotine. Bioorg Med Chem. 2004 Feb 1;12(3):563-70. PMID:14738965 |
Note on publication | The paper describes the use of this antibody in the immunopharmacotherapy for treating nicotine addiction. |
COA Information （For reference only, actual COA shall prevail） | |
Size | 100 μg Purified antibody. |
Concentration | 1 mg/ml. |
Purification | Protein A affinity purified |
Buffer | PBS with 0.02% Proclin 300. |
Concentration | 1 mg/ml. |
Storage Recommendation | Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C. |
